Company intelligence / Profile preview

Shanghai Zhangjiang Biotechnology

Shanghai, Shanghai, Chinaprnewswire.com ↗

Ownership: Private
Employees: ~600
Development stage: Phase 2

Overview

The company has several approved products including hemoporfin for port wine stain and aminolevulinic acid hydrochloride for various indications. Multiple ADC candidates are in clinical trials, with FDA022 (HER2 x Top I) in Phase 2, and FDA018 (Trop-2 x Top I) and FZ-AD005 (DLL3 x Top I) in Phase 1.

Therapeutic areas: GastroenterologyImmunologyDermatologyOncologyNeurologyInfectious Diseases
Modalities: Antibody-drug conjugates (ADCs)Monoclonal antibodiesBiosimilarsFusion proteinsLiposomal drugsSmall molecule drugsGenetic engineering drugsPhotodynamic technology drugsNano technology drugsOral solid preparation technology drugs
Industry: Biotech

Drug pipeline

1 asset

CMAB820

Unknown

Beyond the preview

Go deeper on Shanghai Zhangjiang Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Zhangjiang Biotechnology.

Explore the full profile